Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback